Abstract: The disclosure provides cosmetic and therapeutic compositions of alpha-adrenergic agents. Compositions of the disclosure may be used for topical, transdermal or parenteral administration to the eye or eyelid. The compositions of the disclosure may be used cosmetically to improve the appearance of the eye or therapeutically to treat ptosis.

Abstract: Systems and methods for performing Direct Sodium Removal (DSR) therapy are provided in which an implantable device includes a pump coupled to an inlet catheter designed for placement in a patient's peritoneal cavity, an outlet catheter designed to be coupled to the patient's bladder, and is operably coupled to an analyte sensor, the pump programmed to transfer and/or cease transfer of fluid from the patient's peritoneal cavity to the patient's bladder for voiding responsive to a level of analyte detected by the analyte sensor. In addition, the system may include a processor that computes an amount of analyte transferred per pumping session.

Abstract: In one embodiment, an electroactive material includes a piezoelectric polymer substrate and a conducting polymer coating provided on the substrate.

Abstract: A device for injecting a therapeutic agent into an ocular implant at least partially implanted in an eye including an injection lumen providing a pathway for injecting the therapeutic agent into the implant; an outlet lumen providing a pathway for pre-existing fluid in the ocular implant to exit the implant; and a collection chamber fluidly coupled to the outlet lumen that provides a first fluid outflow resistance and a second fluid outflow resistance. The first fluid outflow resistance is lower than a first resistance to outflow of the implant. The second fluid outflow resistance is greater than a force imparted onto the implant by intraocular pressure of the eye. Injection of therapeutic agent into the implant via the injection lumen causes the pre-existing fluid to exit the implant and enter the collection chamber via the outlet lumen and causes a second pre-existing fluid to displace from the collection chamber.

Abstract: The invention relates to a composition comprising: (a) one or more alkoxysilanes comprising solubilizing function(s) of formula R1Si(OR2)z(R3)x(OH)y, and/or hydrolysis products thereof and/or oligomers thereof, (b) one or more of formula (R4)mSi(OR5)n and/or hydrolysis products thereof and/or oligomers thereof, et (c) one or more surfactants. It also relates to the use thereof for cleansing and/or conditioning keratin fibres.

Abstract: In some embodiments, a method of fabricating a skin wound patch includes preparing a biopolymeric solution comprising chitosan, collagen, chondroitin sulfate, elastin, hyaluronic acid, follistatin-like 1 (FSTL-1), iron oxide nanoparticles, and AC2-26 peptide, filtering the biopolymeric solutions through a filter membrane, extruding the biopolymeric solution through an extrusion device to form a nanofibrous composite, collecting the extruded nanofibrous composite on a sterilized plate, and drying the extruded nanofibrous composite into a solid patch. In some embodiments, a skin wound patch includes homogeneously distributed biomolecules, skin materials, pro-inflammatory, and antibacterial agents. In further embodiments, a method of treating a chronic skin wound in a subject in need thereof can include applying any of the patches described herein.

Abstract: The instant invention provides for novel lipid nanoparticle (LNP) formulations, containing cationic lipids, for use as vaccine adjuvants and/or as antigen delivery systems. It is an object of the instant invention to provide LNP formulations that demonstrate enhancements in humoral and/or cellular immunogenicity of vaccine antigens, particularly subunit vaccine antigens, when utilized alone or in combination with immunostimulatory agents (e.g. small molecule or oligonucleotide TLR agonists). The instant invention further identifies physical and chemical properties of the LNP formulations that can be manipulated to enhance antigen efficiency and adjuvant tolerability in vivo.

Abstract: Disclosed are a sustained-release injection formulation containing a biodegradable polymer microcapsule that contains a conjugate of poly-L-lactic acid (hereinafter referred to as “PLLA”) filler and hyaluronic acid (hereinafter referred to as “HA”) and contains a PLLA-HA microcapsule, and a method of preparing the same.

Abstract: An injectable hydrogel composition that forms a porous gel rapidly after injection fro tissue engineering. The composition comprises a biodegradable, biocompatible, gelling polymer, that is optionally reverse-gelling; an Extra cellular matrix (ECM) material and a biocompatible porogen. Methods of making and using the composition are provided. A kit also is provided comprising the ingredients for making the hydrogel.

Abstract: The present invention relates to a method for constructing a whitlockite coating on a surface of a calcium phosphate-based bioceramic substrate and a resulting coating, wherein the preparation method includes the following steps of: preparing pure calcium phosphate-based bioceramic powder firstly, then pre-firing, shaping and calcining the pure calcium phosphate-based bioceramic powder to obtain a calcium phosphate-based bioceramic substrate, placing the substrate in a solution containing Mg2+, then transferring the substrate to a high-temperature high-pressure reaction kettle for a hydrothermal reaction, and then cleaning and drying the sample to obtain a whitlockite coating.

Abstract: The subject of the invention is a wax-in-water emulsion containing at least one fatty acid ester of tetramethylpropylethylenediamine, which is intended to replace triethanolamine, known to decompose into nitrosamines when the preserved emulsion is packaged in a thermoplastic material. Moreover, this emulsion has the advantage of gaining shade depth and fluidity, especially in products rich in waxes.

Abstract: Cosmetic composition comprising anionic surfactants, amphoteric surfactants, cationic polymers and liquid fatty substances chosen from fatty alcohols and fatty esters, and cosmetic treatment process The present invention relates to a cosmetic composition, especially a hair composition, comprising: —one or more anionic surfactants, —one or more amphoteric surfactants, —one or more cationic polymers with a high cationic charge density, —one or more liquid fatty substances chosen from non-oxyalkylenated fatty alcohols and monocarboxylic fatty acid esters, and also mixtures thereof. The invention also relates to a cosmetic process for treating, and more particularly for washing and conditioning, keratin materials, especially the hair, using the present composition.

Abstract: The present invention relates to an antibacterial co-polymer comprising a water soluble backbone polymer having in at least one end a dendritic or hyperbranched polymer of generation 1 to 6 wherein at least one functional group comprising a carboxylic amine has been covalently attached to the periphery of the dendritic or hyperbranched polymer. The present invention also relates to said anti-bacterial co-polymer when said co-polymer has been cross-linked with a cross-linking agent and to uses of the cross-linked co-polymer in a hydrogel for the treatment or prevention of bacterial infections, particularly in surgical site infections (SSIs).

Abstract: The present invention relates to a fibrous nerve conduit for promoting nerve regeneration, comprising a channel, the channel having diameter controllable ends, the channel is adjustable to suturing to a proximal and distal end of a severed nerve, the conduit further comprises a PCL (MW:70KDa) with concentration of 10-15% and PLGA (MW:50KDa,50:50) with concentration of 10-18%.

Abstract: The present invention relates to a cosmetic system comprising an applicator and a gel composition, and methods for making-up and enhancing the appearance of keratinous materials using the systems.

Abstract: Disclosed is a nano-layered dual hydroxide-biological factor combined system for promoting nerve regeneration to repair a spinal cord injury. The preparation method therefor comprises: 1) synthesizing a nano-layered dual hydroxide CL1; and 2) co-incubating 10 mg CL1 and 200-2000 ng of biological factors NT3, VEGF or bFGF in a low-speed shaker at 4° C. for 2 hours using an ion exchange method, centrifuging same and then obtaining the precipitate. Experiments on transection and resorption spinal cord injury models show that this combined system has a significant recovery effect on the behavior of model mice, can reconstruct the neural circuit of a damaged area over time and achieves an ideal repair effect with regard to a spinal cord injury.

Abstract: A preparation method and an application of a composite scaffold for directionally guiding regeneration of optic nerve axons. A major component of the composite scaffold is prepared from one or more degradable biomedical materials combined according to different ratios by a gradient freezing method. To increase a mechanical property of the scaffold or prolong in-vivo degradation time, the scaffold may be cross-linked by a biological cross-linker. After a gelatin is added, the prepared composite scaffold exhibits excellent mechanical properties and biocompatibility. A problem of solubility differences of the gelatin A produced during gradient freezing can be regulated by sodium alginate, thereby facilitating regular directional pipeline morphology of the scaffold.

Abstract: The present invention relates to coated silk films. Further, the present invention relates to pharmaceutical or cosmetic compositions comprising the coated silk films. Furthermore, the present invention relates to coated silk films or pharmaceutical compositions comprising the coated silk films for use in medicine. In addition, the present invention relates to methods of producing the coated silk films.

Abstract: Provided herein is a novel method for creating fixed, non-antagonistic molar ratios of drugs in and around the bone environment for desired periods of time. This method enables treating bone and bone-related disease by administering a pharmaceutical composition comprising a bone-targeted therapeutic agent able to release a drug payload from the bone surface, in addition to a second therapeutic agent. Such methods are useful in the treatment of bone and bone-related diseases, such as cancer-induced bone disease, osteomyelitis and bone infection, bone pain and inflammatory bone disease, metabolic disease, as well as others.

Abstract: The present invention is directed to targeted delivery of a cold slurry underneath a patient's skin to improve the cosmetic appearance of the skin. The “target” tissue can be muscle tissue that when cooled cannot contract and cause wrinkles/lines in the skin to appear. The target tissue can also be adipose tissue that causes overlying tissue to sag and form wrinkles/lines. The cold slurry induces apoptosis, and reduces the size of the tissue, and causes the connective tissue supporting the skin to thicken and tighten, thereby reducing wrinkles/lines. Skin can also be tightened with cold slurry injected into the dermis layer of the skin or within the layers of the oral mucosa making a cold slurry treatment ideal for reducing the appearance of baggy skin after a patient loses weight and or for treating obstructive sleep apnea. Cold slurry can also be used to treat cellulite and acne.